马用药物和补充剂市场按产品类型、治疗类别、分销管道、给药途径、最终用户、剂型和动物年龄组划分 - 全球预测 2025-2032

预计到 2032 年，马用药物和补充剂市场规模将成长至 15.6293 亿美元，复合年增长率为 5.96%。

主要市场统计数据
基准年2024年	9.8349亿美元
预计2025年	10.434亿美元
预测年份：2032年	1,562,930,000美元
复合年增长率（%）	5.96%

马疗法简明说明，重点在于临床重点、监管环境和医疗保健环境中相关人员的期望

马用药物和补充剂领域需要重点关注，以平衡临床需求、监管监督和商业性可行性。日益复杂的治疗方法、多样化的最终用户和多样化的剂型共同构成了一个以准确性、安全性和可靠供应为首要考虑的环境。兽医和牧场主需要能够为成年马、幼马和一岁马带来可预测结果的产品，而研究实验室和医院则优先考虑有实证依据的配方和强大的不利事件监测。

同时，研究机构和医院优先考虑有实证依据的配方和强有力的不利事件监测。无论产品类型如何，药品仍然是急性疾病和特异性疾病治疗的核心，而补充剂则越来越多地用于预防性护理、体能支持和长期肌肉骨骼健康。同时，分销管道正从传统的兽药店扩展到线上药局和综合医院管道，这为低温运输管理、认证和法规遵从性带来了新的考量。从概念到临床的转变也涉及应对不断发展的治疗类别，例如抗感染药感染疾病和抗发炎药物，这些药物的剂型和给药途径对临床应用有重大影响。

这些动态的结合需要研发、生产、监管和商业团队之间的策略合作。专注于临床效用、安全性和分销完整性，使相关人员能够优先考虑能够在马匹医疗保健领域带来可衡量价值的投资和介入措施。

技术创新、监管现代化和不断发展的兽医护理模式如何从根本上改变马疗法的产品开发和交付

多种力量的交会重塑了马匹治疗的格局，这些力量正在改变产品的开发、检验和交付方式。生技药品和疫苗平台的进步使得更有针对性的预防方法成为可能，而抗菌药物管理的必要性则推动配方师和开发团队朝着更复杂的抗感染疾病策略和替代支持模式迈进。同时，数位健康工具和远端医疗正在改变兽医咨询时间，实现远端监控，并影响产品的配製方式和依从性追踪。

供应链和生产实践也在不断发展。随着企业寻求缩短前置作业时间并减少对单一原料药)来源的依赖，契约製造和区域生产中心日益受到青睐。同时，电子商务和直销管道迫使企业重新思考包装、序列化和低温运输通讯协定，以维持产品完整性和监管可追溯性。与此转变相辅相成的是，企业更加重视配方科学，外用凝胶、口服粉剂和注射剂等创新产品提高了生物有效性和使用者便利性。

这种转型为差异化提案主张创造了机会，但也对跨职能协调提出了新的要求。将临床证据产生与灵活的生产、数位化分销和清晰的监管策略相结合的公司将更有能力将创新转化为商业性和临床影响力。

评估 2025 年实施的美国关税对马匹医疗保健价值链的多方面营运、临床和策略影响

2025年美国关税对涉及马科动物药品和补充剂的组织的战略考量产生了重大且多方面的影响。进口活性成分和成品的成本结构受到直接影响，促使采购团队重新评估其供应商组合，并加快寻找替代供应商的资格。在实践中，这导致企业更加重视区域采购、库存缓衝，在某些情况下，甚至将关键製造流程回流或近岸外包，以降低未来的关税风险。

除了采购之外，为了最大程度地降低关税的影响，企业重新平衡物流，分销模式也改变了。这种重组增加了对具有跨境能力的委託製造和第三方物流供应商的需求，并提高了关税分类、原产地证明和贸易合规专业知识在商业运营中的重要性。小型製造商和专业药局感受到了不成比例的压力，因为它们通常缺乏应对成本衝击或协商批量采购折扣的灵活性。

在临床方面，关税环境加剧了与动物用药品客户的价格谈判，并促使企业重新关注成本效益和治疗差异化。因此，产品团队优先投资于能够提高製剂效率、延长保质期并实现低成本给药途径的专案。从策略角度来看，关税引发了全行业对供应链弹性、企业税务规划以及区域化製造地与全球优化但受政策影响的供应链之间的利弊的重新评估。

可操作的细分资讯揭示了产品类型、治疗层级、分销管道、给药途径、最终用户、配方和年龄组如何影响临床采用

当考虑产品类型、治疗层级、分布、给药途径、最终用户、配方和年龄层时，会发现几个清晰的模式。药品和补充剂作为互补类别发挥作用，药品优先用于急性和疾病特异性干预，而补充剂更常用于长期护理计划中的预防和结缔组织支持。在治疗类别中，感染疾病和抗发炎药物仍然是临床实践的核心支柱。当需要经验性治疗时，感染疾病着重于Aminoglycosides、大环内酯类、青霉素类、磺胺类药物和四环霉素。抗发炎药物平衡皮质类固醇策略和非类固醇抗发炎药物方案，以控制疼痛和炎症，同时最大限度地降低系统性风险。

随着兽医和医院越来越多地从线上药局和综合兽医管道获取药物，分销偏好正在发生变化，这减少了重复处方笺的摩擦，并实现了依从性追踪。注射剂仍然是许多急性和住院治疗的必需品，可根据剂量要求和耐受性选择肌肉注射、静脉注射和皮下注射等给药方式。口服製剂，尤其是粉末、糖浆和片剂，是门诊治疗的首选，尤其是在马驹偏好和剂量准确性至关重要的情况下。外用製剂，例如乳膏、乳剂和凝胶，旨在局部治疗，以减少全身暴露并支持肌肉骨骼和皮肤疾病的恢復。

终端使用者细分显示，马场和兽医诊所是高价值治疗产品的主要购买者，而研究机构和门诊服务则日益成为新型生技药品和疫苗的早期采用者。因此，製剂选择必须兼顾现场从业人员的操作偏好和医院药局的稳定性要求。此外，成年马通常需要以肌肉骨骼健康和循环系统支持为重点的慢性病管理方案，幼马需要更温和的口服药物和谨慎注射的注射剂，而一岁马则处于过渡期，通常同时使用预防性补充剂和标准药物。整合这些细分市场，产品团队能够更好地将开发重点与使用者工作流程和临床决策标准结合。

区域情报揭示美洲、欧洲、中东、非洲和亚太地区马药市场的需求驱动因素、监管变化和商业化策略

区域动态塑造需求驱动因素、监管预期和商业化策略，而这些因素往往被全球产品团队低估。美洲拥有相对先进的临床基础设施，主要集中在大型兽医院和专科马科诊所，有力地支持了实证医学和优质补充剂的发展。该地区的临床方案和付款人模式鼓励对新型疫苗和生技药品的投资，而成熟的分销网络则支持诊所直销和线上药房管道。

在欧洲、中东和非洲，监管的多样性和农场结构的差异导致了商业性模式的复杂化。欧洲市场强调严格的药物安全检测和抗菌药物管理，这会影响某些全身性药物的标籤检视、使用指南和可接受性。中东和非洲次区域由于进口物流、低温运输基础设施和区域特定疾病压力的差异，增加了额外的复杂性，所有这些都影响了产品优先顺序和市场进入策略。

亚太地区正经历着都市区兽医诊所的快速应用以及新兴马术休閒和运动领域需求的成长。虽然该地区的製造能力和原材料采购有利于供应的连续性，但不同市场的法律规范和进口惯例差异很大。贸易政策和关税动态持续影响着各地区的采购决策，而那些制定以区域为重点的监管备案、经销伙伴和定价策略的公司将占据有利地位，能够抓住任何需求。

专注于创新、製造策略和伙伴关係模式的竞争与合作观点塑造了马疗法领域的领导力

马科动物治疗领域的竞争格局以大型动物用药品公司、专业动物用药品公司、生物技术公司和复合药房为特征。老字型大小企业利用其广泛的製造地、多样化的产品组合和全球分销协议来推动临床渗透。这些公司往往优先考虑实证医学证据丰富的产品，例如疫苗、循环系统药物和关键抗感染药感染疾病，同时也投资于生命週期管理和配方改进，以维持临床偏好。

参与企业和生物技术参与企业正透过有针对性的创新来脱颖而出，例如下一代生技药品、改进的止痛方式以及提高生物有效性并减少给药频率的配方科学。这些公司经常与研究机构和兽医诊所建立策略联盟，以加速临床检验并获得早期采用者群体。受託製造厂商和第三方物流供应商正成为竞争定位的核心，能够在限制资本支出的同时，实现更快的市场进入和灵活的规模扩张。

总体而言，成功的策略将包括整合的商业模式，该模式将清晰地描述临床价值、严格的监管申报、与兽医的直接互动、数位教育平台以及高效的分销相结合。能够展示可重复的临床结果、确保供应链弹性并为最终用户提供有效支援服务的公司通常将获得更强大的市场吸引力，并建立更持久的客户关係。

为领导者提供实用且优先的建议，以加强供应弹性、扩大临床证据并优化马匹护理的商业化。

产业领导者应协同采取一系列行动，以增强韧性，加速临床应用，并改善商业性成果。首先，透过多元化供应网络和加快替代原料药和最终产品来源的认证，减轻政策衝击和关税导致的成本波动的影响。同时，优先投资于製剂科学，以降低给药复杂性，提高在不同物流条件下的稳定性，并解决特定年龄层的耐受性，从而提高农民和门诊病人在现实世界中的依从性。

第二，我们将透过有针对性的临床证据产生和以从业人员为中心的教育项目，深化与兽医相关人员的合作。我们将产生可操作的临床数据，突显成本效益、安全性和易用性，从而支持医院、诊所和农场管理者采用此技术。第三，我们将结合诊所直销模式和高效的线上药局管道，优化分销，确保产品序列化和可追溯性，以维护产品完整性并打击假冒仿冒品。

第四，制定监管和贸易合规策略，以因应关税变化和不同的区域要求。透过提升关税分类、原产国文件和监管协调方面的能力，加快市场进入并缩短上市时间。最后，探索与契约製造製造商、研究机构和技术提供者的合作，以共用担风险、加速创新并配套服务，从而提升从业者的价值提案。这些合作措施将有助于永续成长，同时管理短期营运风险。

我们的研究结果以透明的混合方法研究途径为基础，该方法结合了相关人员访谈、文献综述、细分框架和检验通讯协定。

本文呈现的研究结果源自于混合方法研究途径，旨在平衡主要利害关係人的见解和严谨的二手证据。主要资料收集包括对执业相关人员、医院管理人员、马场采购人员、配方科学家和高级公司高管的结构化访谈，提供有关临床决策驱动因素和营运限制的一线观点。这些定性资讯还辅以同行评审的临床文献、监管指南、专利申请和公开的临床试验註册库，以确保技术准确性并揭示新兴创新。

所采用的分析架构包括跨产品类型、治疗类别、分销管道、给药途径、最终用户、剂型和年龄组的細項分析，以及用于评估干预措施和供应链突发事件的情境规划。为了检验研究结果，我们采用了多阶段的三角测量法，将访谈证据与第二手资料和跨区域贸易资料结合。专家小组审查提供了进一步的检验，重点关注临床和商业性相关性。研究的局限性包括数据可用性的地区差异以及干预措施的不断发展变化，这些变化可能会改变竞争格局。在适当的情况下，方法附录中提供了假设和置信水平，以帮助解释。

总结性综合报告重点强调了马匹治疗生态系统相关人员的策略重点、新兴风险和机会途径

最后，马科动物药品和补充剂行业的相关人员必须应对双重挑战：一方面要提供临床上可靠且用户友好的治疗方法，另一方面要管理日益复杂的政策和供应链环境。治疗重点、不断发展的分销管道以及区域监管差异之间的相互作用，需要灵活的筹资策略、清晰的临床证据和灵活的商业模式。 2025年推出的关税趋势凸显了供应链多元化和主动贸易合规的必要性，这将促使策略转变，这将在可预见的未来影响采购和製造决策。

同样重要的是，产品开发应与实际兽医工作流程和年龄组给药保持一致，以确保配方符合马场、门诊、研究实验室和医院的实际需求。将严格的临床检验与灵活的生产安排和地理策略结合的组织，将最有可能获得持续的价值。最终，最成功的公司将是那些将创新与明确的从业者利益相结合，同时保持营运韧性以应对外部衝击的公司。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 快速采用标靶单株抗体疗法治疗马蹄叶炎
• 结合益生元和益生菌的合合益素元配方对马肠道健康的需求日益增长
• 植物来源黄酮类化合物在治疗马关节炎和运动功能的应用日益增多
• 扩展的马营养基因组检测服务允许客製化营养补充方案
• 严格的欧盟法规推动马疗法核准和合规途径的创新
• 增加註射长效止痛药的使用以改善马术后疼痛管理
• 开发水溶性维生素复合物以维持比赛马的电解质平衡
• 整合人工智慧驱动的性能遥测技术，以优化马匹补充计画和剂量
• 专注于可持续来源的海洋胶原蛋白和Omega-3酸，用于马皮和关节营养

第六章 2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 马用药品和补品市场（依产品类型）

• 製药
• 补充

9. 马用药物和补充剂市场（按治疗类别）

• 麻醉剂
• 抗感染药物
  • Aminoglycosides
  • 大环内酯类
  • 青霉素
  • 磺胺类药物
  • 四环霉素
• 抗发炎药物
  • 皮质类固醇
  • NSAIDs
• 心血管药物
• 胃肠药
• 荷尔蒙製剂
• 神经系统药物
• 疫苗

第 10 章。马药和补品市场（按分销管道）

• 网路药局
• 零售药局
• 兽医诊所
• 兽医药房

第 11 章。按给药途径分類的马用药物和补充剂市场

• 注射
  • 肌肉注射
  • 静脉
  • 皮下
• 口服
  • 粉末
  • 糖浆
  • 药片
• 局部的

第 12 章：马用药品和补品市场（依最终用户划分）

• 马场
• 研究和学术机构
• 兽医诊所和门诊服务
• 兽医诊所

第 13 章：马用药品和补充剂市场（按剂型）

• 奶油
• 乳剂
• 凝胶
• 粉末
• 解决方案
• 药片

第 14 章。马用药品和补品市场（以动物年龄层）

• 成年马
• 驹
• 一岁鸽

第十五章 马用药品和补品市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第 16 章：马用药品和补品市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第 17 章：按国家分類的马药和补品市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十八章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Boehringer Ingelheim Animal Health GmbH
  • Elanco Animal Health Incorporated
  • Ceva Sante Animale SAS
  • Dechra Pharmaceuticals plc
  • Virbac SA
  • Vetoquinol SA
  • Phibro Animal Health Corporation
  • Neogen Corporation

The Equine Pharmaceuticals & Supplements Market is projected to grow by USD 1,562.93 million at a CAGR of 5.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 983.49 million
Estimated Year [2025]	USD 1,043.40 million
Forecast Year [2032]	USD 1,562.93 million
CAGR (%)	5.96%

A concise orientation to the equine therapeutics landscape highlighting clinical priorities, regulatory responsibilities, and stakeholder expectations across care settings

The equine pharmaceuticals and supplements domain demands a focused orientation that balances clinical need, regulatory oversight, and commercial practicality. Increasingly complex therapeutic regimens, diversified end users, and a broader array of delivery formats have combined to create a landscape where precision, safety, and supply reliability are paramount. Veterinarians and farm managers require products that deliver predictable outcomes across adult horses, foals, and yearlings, while research institutions and hospitals prioritize evidence-backed formulations and robust adverse event monitoring.

Across product distinctions, pharmaceuticals continue to anchor acute care and disease-specific treatments, while supplements are often deployed for preventive care, performance support, and long-term musculoskeletal health. Meanwhile, distribution has broadened beyond traditional veterinary pharmacies to include online pharmacies and integrated hospital channels, introducing new considerations around cold-chain management, authentication, and regulatory compliance. Transitioning from concept to clinic also involves navigating evolving therapeutic categories such as anti-infectives and anti-inflammatories, where formulation and route of administration materially impact clinical adoption.

Taken together, these dynamics require strategic alignment across R&D, manufacturing, regulatory affairs, and commercial teams. By foregrounding clinical utility, safety, and distribution integrity, stakeholders can better prioritize investments and interventions that deliver measurable value in equine care settings.

How technological innovation, regulatory modernization, and evolving veterinary care models are fundamentally altering product development and delivery in equine therapeutics

The equine therapeutics landscape is being reshaped by multiple intersecting forces that are altering how products are developed, validated, and delivered. Advances in biologics and vaccine platforms are enabling more targeted preventive approaches, even as antimicrobial stewardship imperatives push formulators and prescribers toward refined anti-infective strategies and alternative supportive modalities. Concurrently, digital health tools and telemedicine are changing the cadence of veterinary consultations and enabling remote monitoring, which affects how products are prescribed and how adherence is tracked.

Supply chain and manufacturing practices are also evolving. Contract manufacturing and regional production hubs are gaining traction as companies seek to shorten lead times and reduce reliance on single-source active pharmaceutical ingredient suppliers. At the same time, e-commerce and direct-to-practice distribution channels are forcing companies to rethink packaging, serialization, and cold-chain protocols to maintain product integrity and regulatory traceability. These shifts are complemented by a heightened focus on formulation science, where innovations in topical gels, oral powders, and injectable presentations are improving bioavailability and user convenience.

Together, these transformations create opportunities for differentiated value propositions, but they also impose new requirements for cross-functional coordination. Firms that align clinical evidence generation with flexible manufacturing, digital-enabled distribution, and clear regulatory strategies will be better positioned to translate innovation into commercial and clinical impact.

Assessing the multifaceted operational, clinical, and strategic consequences of the United States tariff measures introduced in 2025 on the equine therapeutics value chain

The 2025 tariff measures introduced by the United States have had a material and multifaceted influence on the operational and strategic calculus of organizations involved in equine pharmaceuticals and supplements. Cost structures for imported active ingredients and finished goods were directly affected, prompting procurement teams to reassess supplier portfolios and to accelerate qualification of alternative sources. In practice, this has meant a stronger emphasis on regional sourcing, inventory buffering, and in some cases, reshoring or nearshoring of critical manufacturing steps to mitigate future policy risk.

Beyond procurement, distribution patterns shifted as companies rebalanced logistics to minimize tariff exposure. This rebalancing increased demand for contract manufacturers and third-party logistics providers with cross-border capabilities, and it elevated the importance of tariff classification, origin documentation, and trade compliance expertise within commercial operations. Smaller manufacturers and specialized compounding pharmacies felt disproportionate pressure, as they typically have less flexibility to absorb cost shocks or negotiate bulk purchase discounts.

Clinically, the tariff environment translated into tighter price negotiations with veterinary customers and a renewed focus on demonstrating cost-effectiveness and therapeutic differentiation. As a result, product teams prioritized investments that enhanced formulation efficiency, extended shelf life, or enabled lower-cost routes of administration. From a strategic perspective, the tariffs catalyzed a broader industry reassessment of supply chain resilience, corporate tax planning, and the merits of localized manufacturing footprints versus a globally optimized but policy-exposed supply chain.

Actionable segmentation intelligence revealing how product types, therapeutic classes, distribution channels, administration routes, end users, formulations, and age groups inform clinical adoption

Segmentation offers the most direct route to actionable differentiation in equine therapeutics, and several clear patterns emerge when product type, therapeutic class, distribution, route of administration, end user, formulation, and animal age group are considered together. Pharmaceuticals and supplements function as complementary categories; pharmaceuticals are prioritized for acute and disease-specific interventions, while supplements are more commonly adopted for preventive and connective tissue support across long-term care plans. Within therapeutic categories, anti-infectives and anti-inflammatories remain core pillars of clinical practice, with anti-infectives emphasizing agents such as aminoglycosides, macrolides, penicillins, sulfonamides, and tetracyclines when empirical coverage is needed, and anti-inflammatories balancing corticosteroid strategies against NSAID regimens to manage pain and inflammation while minimizing systemic risk.

Distribution preferences are shifting as veterinarians and hospitals increasingly source through online pharmacies and integrated veterinary hospital channels, reducing friction for repeat prescriptions and enabling better adherence tracking. Injectable presentations continue to be essential for many acute and inpatient interventions, with intramuscular, intravenous, and subcutaneous options selected based on onset requirements and tolerability. Oral forms, particularly powders, syrups, and tablets, are favored for outpatient management and for foals where palatability and dosing precision are critical. Topical formulations, including creams, emulsions, and gels, offer targeted local therapy that reduces systemic exposure and supports recovery in musculoskeletal and dermatological conditions.

End-user segmentation reveals that equine farms and veterinary hospitals are primary purchasers of high-value therapeutic products, whereas research institutions and ambulatory services increasingly influence early adoption of novel biologics and vaccines. Formulation choices must therefore reconcile handling preferences of field practitioners with the stability demands of hospital pharmacies. Moreover, age-group considerations are integral to product positioning: adult horses often require chronic management solutions focused on musculoskeletal health and cardiovascular support, foals demand gentler oral and injectables with careful dosing, and yearlings fall into a transitional category where both preventive supplements and standard pharmaceuticals are commonly used. By integrating these segmentation dimensions, product teams can better align development priorities with user workflows and clinical decision-making criteria.

Regional intelligence unpacking demand drivers, regulatory variation, and commercialization strategies across the Americas, EMEA, and Asia-Pacific equine care markets

Regional dynamics shape demand drivers, regulatory expectations, and commercialization strategies in ways that are often underappreciated by global product teams. In the Americas, clinical infrastructures are relatively advanced and concentrated in high-volume veterinary hospitals and specialist equine clinics, yielding strong uptake of evidence-backed pharmaceuticals and premium supplements. Clinical protocols and payer models in this region encourage investment in novel vaccines and biologics, and the presence of well-established distribution networks supports both direct-to-practice and online pharmacy channels.

In Europe, Middle East and Africa, regulatory heterogeneity and differing farm structures create a mosaic of commercial approaches. European markets emphasize stringent pharmacovigilance and antimicrobial stewardship, which affects labeling, usage guidance, and the acceptability of certain systemic agents. Middle Eastern and African subregions introduce additional complexity with variations in import logistics, cold-chain infrastructure, and localized disease pressure, all of which influence product prioritization and go-to-market tactics.

Asia-Pacific presents a distinct mix of rapid adoption in urban veterinary centers and growing demand from emerging equine leisure and sport segments. Manufacturing capacity and ingredient sourcing in the region can be advantageous for supply continuity, yet regulatory frameworks and import practices vary considerably from market to market. Across all regions, trade policies and tariff dynamics continue to exert influence on sourcing decisions, and companies that craft region-specific regulatory filings, distribution partnerships, and pricing strategies will be better positioned to capture the full spectrum of demand.

Competitive and collaborative company-level perspectives emphasizing innovation focus, manufacturing strategy, and partnership models shaping equine therapeutics leadership

Competitive landscapes in equine therapeutics are characterized by a mixture of large animal health companies, specialized veterinary pharmaceutical firms, biotech innovators, and compounding pharmacies. Established firms often leverage broad manufacturing footprints, diversified portfolios, and global distribution agreements to support widespread clinical penetration. They tend to prioritize high-evidence products such as vaccines, cardiovascular agents, and key anti-infectives, while also investing in lifecycle management and formulation improvements to retain clinical preference.

Specialist players and biotech entrants are differentiating through targeted innovation, such as next-generation biologics, improved analgesic modalities, and formulation science that enhances bioavailability or reduces administration frequency. These firms frequently pursue strategic partnerships with research institutions and veterinary hospitals to accelerate clinical validation and to access early-adopter cohorts. Contract manufacturing organizations and third-party logistics providers are increasingly central to competitive positioning, enabling faster market entry and flexible scaling while allowing companies to control capital expenditure.

Across the competitive set, successful strategies include clear articulation of clinical value, robust regulatory dossiers, and integrated commercial models that combine direct engagement with veterinarians, digital education platforms, and efficient distribution. Firms that can demonstrate reproducible clinical outcomes, secure supply chain resilience, and offer effective support services for end users will generally achieve stronger market traction and more durable customer relationships.

Practical and prioritized recommendations for leaders to reinforce supply resilience, amplify clinical evidence, and optimize commercialization in equine therapies

Industry leaders should pursue a coordinated set of actions that enhance resilience, accelerate clinical adoption, and improve commercial outcomes. First, diversify supplier networks and accelerate qualification of alternative API and finished-goods sources to reduce exposure to policy shocks and tariff-driven cost volatility. Concurrently, prioritize investments in formulation science that lower administration complexity, improve stability under varied logistics conditions, and address specific age-group tolerability, thereby increasing real-world adherence among farm-based and ambulatory users.

Second, deepen engagement with veterinary stakeholders through targeted clinical evidence generation and practitioner-focused education programs. Generating pragmatic clinical data that highlights cost-effectiveness, safety, and ease of administration will support uptake among hospitals, clinics, and farm managers. Third, optimize distribution by combining direct-to-practice models with validated online pharmacy channels, ensuring serialization and traceability to preserve product integrity and combat counterfeiting.

Fourth, prepare regulatory and trade-compliance strategies that anticipate tariff shifts and heterogeneous regional requirements. Building capabilities in tariff classification, origin documentation, and regulatory harmonization will accelerate market access and reduce time-to-shelf. Finally, explore collaborative ventures with contract manufacturers, research institutions, and technology providers to share risk, accelerate innovation, and create bundled service offerings that enhance practitioner value propositions. These coordinated measures will support sustainable growth while managing near-term operational exposure.

Transparent mixed-methods research approach combining stakeholder interviews, literature review, segmentation frameworks, and validation protocols to underpin findings

The findings presented here are derived from a mixed-methods research approach designed to balance primary stakeholder insight with rigorous secondary evidence. Primary data collection included structured interviews with practicing veterinarians, hospital administrators, procurement leads at equine farms, formulation scientists, and senior commercial executives, providing frontline perspectives on clinical decision drivers and operational constraints. These qualitative inputs were complemented by a review of peer-reviewed clinical literature, regulatory guidance, patent filings, and publicly available clinical trial registries to ensure technical accuracy and to contextualize emergent innovations.

Analytical frameworks employed include segmentation analysis across product type, therapeutic category, distribution channel, route of administration, end user, formulation, and age group, as well as scenario planning to evaluate policy and supply chain contingencies. Triangulation was used at multiple stages to validate insights, combining interview evidence with secondary documentation and cross-regional trade data. An expert panel review provided an additional layer of validation, focusing on clinical plausibility and commercial relevance. Limitations include regional variation in data availability and the evolving nature of policy interventions that may change the competitive environment; where appropriate, assumptions and confidence levels are documented in the methodology annex to aid interpretation.

Concluding synthesis crystallizing strategic priorities, emergent risks, and opportunity pathways for stakeholders across the equine therapeutics ecosystem

In closing, stakeholders operating in the equine pharmaceuticals and supplements sector must reconcile a dual imperative: deliver clinically robust, user-friendly therapies while managing an increasingly complex policy and supply chain environment. The interplay of therapeutic priorities, distribution channel evolution, and regional regulatory variation requires nimble sourcing strategies, clear clinical evidence, and adaptive commercial models. Tariff dynamics introduced in 2025 have underscored the necessity of supply chain diversification and proactive trade compliance, catalyzing strategic shifts that will influence sourcing and manufacturing decisions for the foreseeable future.

Equally important is the need to align product development with real-world veterinary workflows and age-specific dosing considerations, ensuring that formulations meet the practical demands of equine farms, ambulatory services, research institutions, and hospitals. Organizations that integrate rigorous clinical validation with flexible manufacturing arrangements and targeted regional strategies will be best placed to capture sustained value. Ultimately, the most successful participants will be those that translate technical innovation into clear practitioner benefits while maintaining operational resilience against external shocks.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid adoption of monoclonal antibody therapies targeting equine laminitis management
• 5.2. Growing demand for synbiotic formulations combining prebiotics and probiotics for equine gut health
• 5.3. Surge in plant-based flavonoid compounds for equine joint inflammation and mobility support
• 5.4. Introduction of digital dosing devices integrating IoT sensors in equine pharmaceutical administration
• 5.5. Expansion of equine nutrigenomic testing services to customize dietary supplement regimens
• 5.6. Stringent EU regulations driving innovation in equine therapeutic approval and compliance pathways
• 5.7. Rising utilization of injectable long-acting analgesics to improve equine postoperative pain control
• 5.8. Development of water-soluble vitamin complexes to address electrolyte imbalance in sport horses
• 5.9. Integration of AI-driven performance telemetry to optimize equine supplement schedules and dosages
• 5.10. Focus on sustainably sourced marine collagen and omega-3 acids for equine coat and joint nutrition

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Equine Pharmaceuticals & Supplements Market, by Product Type

• 8.1. Pharmaceuticals
• 8.2. Supplements

9. Equine Pharmaceuticals & Supplements Market, by Therapeutic Category

• 9.1. Anesthetic Agents
• 9.2. Anti-Infectives
  • 9.2.1. Aminoglycosides
  • 9.2.2. Macrolides
  • 9.2.3. Penicillins
  • 9.2.4. Sulfonamides
  • 9.2.5. Tetracyclines
• 9.3. Anti-Inflammatories
  • 9.3.1. Corticosteroids
  • 9.3.2. NSAIDs
• 9.4. Cardiovascular Agents
• 9.5. Gastrointestinal Agents
• 9.6. Hormonal Preparations
• 9.7. Nervous System Agents
• 9.8. Vaccines

10. Equine Pharmaceuticals & Supplements Market, by Distribution Channel

• 10.1. Online Pharmacies
• 10.2. Retail Pharmacies
• 10.3. Veterinary Hospitals & Clinics
• 10.4. Veterinary Pharmacies

11. Equine Pharmaceuticals & Supplements Market, by Route Of Administration

• 11.1. Injectable
  • 11.1.1. Intramuscular
  • 11.1.2. Intravenous
  • 11.1.3. Subcutaneous
• 11.2. Oral
  • 11.2.1. Powders
  • 11.2.2. Syrups
  • 11.2.3. Tablets
• 11.3. Topical

12. Equine Pharmaceuticals & Supplements Market, by End User

• 12.1. Equine Farms
• 12.2. Research Institutions & Academics
• 12.3. Veterinary Clinics & Ambulatory Services
• 12.4. Veterinary Hospitals

13. Equine Pharmaceuticals & Supplements Market, by Formulation

• 13.1. Creams
• 13.2. Emulsions
• 13.3. Gels
• 13.4. Powders
• 13.5. Solutions
• 13.6. Tablets

14. Equine Pharmaceuticals & Supplements Market, by Animal Age Group

• 14.1. Adult Horses
• 14.2. Foals
• 14.3. Yearlings

15. Equine Pharmaceuticals & Supplements Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Equine Pharmaceuticals & Supplements Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Equine Pharmaceuticals & Supplements Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Analysis
  • 18.3.1. Zoetis Inc.
  • 18.3.2. Merck & Co., Inc.
  • 18.3.3. Boehringer Ingelheim Animal Health GmbH
  • 18.3.4. Elanco Animal Health Incorporated
  • 18.3.5. Ceva Sante Animale SAS
  • 18.3.6. Dechra Pharmaceuticals plc
  • 18.3.7. Virbac SA
  • 18.3.8. Vetoquinol SA
  • 18.3.9. Phibro Animal Health Corporation
  • 18.3.10. Neogen Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AMERICAS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. NORTH AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. LATIN AMERICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. EUROPE EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. MIDDLE EAST EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. AFRICA EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASEAN EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GCC EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. EUROPEAN UNION EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRICS EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. G7 EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NATO EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 34. EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANESTHETIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CARDIOVASCULAR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GASTROINTESTINAL AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY HORMONAL PREPARATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY NERVOUS SYSTEM AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SYRUPS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EQUINE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY CLINICS & AMBULATORY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY EMULSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY ADULT HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL EQUINE PHARMACEUTICALS & SUPPLEMENTS MARKET SIZE, BY FOALS, BY REGION, 20